Research

i-Path launches TMA Toolbox for online biomarker discovery

i-Path has announced the launch of its newest product, the TMA Toolbox. TMA Toolbox boosts i-Path's existing portfolio of digital pathology software services to the research market which includes the bespoke development of image analysis algorithms and digital archiving of biomarker tissue samples.

Medicine from Moss to produce human protein

Biologists at the University of Freiburg, Germany, have produced in the moss bioreactor a human protein, the absence of which leads to age-related blindness in 50 million people. Diabetics use human insulin produced in bacteria in order to treat their metabolic disorder. Many other genetically engineered proteins are also on the advance. They are being used for diagnosis as well as for therapy.

HIV patients may need to start treatment earlier, study suggests

Even HIV (human immunodeficiency virus) patients with relatively high CD4 counts are at an increased risk of death compared to people in the general population, according to a new EU-funded study published in the journal The Lancet. Although the increased risk is relatively small, the findings underline the importance of carrying out further studies into the risks and benefits of starting anti-retroviral therapy (ART) at higher cell counts.

New advances in stem cell treatment for heart damage

Using bone marrow stem cells has already led to huge advances in treating heart attacks and cardiomyopathy. But a new approach, research into which has been partially funded under the Seventh Framework Programme (FP7), is looking even more promising.

New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control

New long term data showed that Vimpat® (lacosamide) provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy.(1) In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents† and those that act on non-sodium channel-targets.(2,3)

Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology

Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.

Opening of Pharmathen's New Ultra-Modern Production Unit in Northern Greece

Marking a new era for Pharmathen's entrepreneurial and economic activity in both the Greek and the international market, the company's new ultra-modern unit at Sapes Rodopi was officially opened today. The new plant was opened by the Deputy Prime Minister, Mr Theodoros Pangalos.

Research & Development

i-Path launches TMA Toolbox for online biomarker discovery

Medicine from Moss to produce human protein

HIV patients may need to start treatment earlier, study suggests

New advances in stem cell treatment for heart damage

New data for Vimpat® (lacosamide) showed sustained efficacy for up to 5 years and improved seizure control

Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology

Opening of Pharmathen's New Ultra-Modern Production Unit in Northern Greece

More Pharma News ...